Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM2006 in advanced solid tumors
NCT07377591Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HDM2006 in solid tumor (advanced stage), sponsored by Huadong Medicine. Primary endpoints: Dose Limiting Toxicity at 21 days, Adverse Events at 30 days and 3 more. Started Dec 2024; status: recruiting.
02
Drugs
HDM2006
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07377591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377591.